COP Research Update — September 22, 2026
Updated Thesis
ConocoPhillips is a global exploration and production company with a portfolio spanning unconventional North American shale, conventional international assets, LNG ventures, and Canadian oil sands, run by a new leadership team after Andy O'Brien became CEO on September 1, 2026. The business quality is medium: it generates substantial cash, with $16.15 in free cash flow per share and a 14.3% return on equity, and it demonstrated operating leverage in the most recent quarter with revenue growth of 36.8% and earnings growth of 99.4% year over year, but it remains a price-taking commodity producer with high sensitivity to crude, bitumen, gas, and NGL differentials, and Q2 2026 production of 2.248 MMBOED was down 143 MBOED from the prior-year quarter while all-in reserve replacement was only 80% at year-end 2025. The shares trade at $127.53 against a blended fair value estimate of $168.50, implying 32.1% upside, and at 7.9 times free cash flow and 6.19 times EV/EBITDA the market is pricing a normalized commodity environment rather than the current cash generation.
The investment grade as of this refresh is B — solid business quality. Medium-tier business, undervalued versus blended fair value with 32.1% upside but very expensive on historical multiples.
Key Metrics at a Glance
- Revenue growth: +36.8% year over year
- Net margin: 14.7%
- Fair value upside: +32.1% to our estimate of $168
Current price: $127.53
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. ConocoPhillips remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full COP research →](/stocks/COP)